Market closedNon-fractional
ALX Oncology/ALXO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
ALXO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
74
Website
www.alxoncology.com
ALX Oncology Metrics
BasicAdvanced
$284M
Market cap
-
P/E ratio
-$3.67
EPS
1.30
Beta
-
Dividend rate
Price and volume
Market cap
$284M
Beta
1.3
Financial strength
Current ratio
5.209
Quick ratio
4.919
Long term debt to equity
9.17
Total debt to equity
10.257
Interest coverage (TTM)
-109.56%
Management effectiveness
Return on assets (TTM)
-44.78%
Return on equity (TTM)
-82.16%
Valuation
Price to book
1.67
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-1.749
Growth
Earnings per share change (TTM)
15.80%
3-year earnings per share growth
20.79%
What the Analysts think about ALX Oncology
Analyst Ratings
Majority rating from 7 analysts.
ALX Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$36M
-21.81%
Profit margin
0.00%
NaN%
ALX Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.84
-$1.24
-$0.93
-$0.71
-
Expected
-$0.88
-$0.87
-$0.84
-$0.84
-$0.76
Surprise
-4.55%
42.53%
10.53%
-15.14%
-
ALX Oncology News
AllArticlesVideos
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Seeking Alpha·1 week ago
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
GlobeNewsWire·1 month ago
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ALX Oncology stock?
ALX Oncology (ALXO) has a market cap of $284M as of July 06, 2024.
What is the P/E ratio for ALX Oncology stock?
The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of July 06, 2024.
Does ALX Oncology stock pay dividends?
No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next ALX Oncology dividend payment date?
ALX Oncology (ALXO) stock does not pay dividends to its shareholders.
What is the beta indicator for ALX Oncology?
ALX Oncology (ALXO) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell ALX Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.